





la fois avant la naissance et pendant l'intrapartum. On pourrait donner plusieurs explications de cette observation apparemment incongrue. Bien qu'il soit normalement facile d'enregistrer la FCF, la qualité du tracé est rarement optimale et elle favorise la totale absence d'uniformité d'interprétation constatée dans les études comparatives des écarts entre les observateurs et chez un même observateur. De plus, on dispose maintenant de nombreuses observations humaines et d'études animales révélant que l'âge gestationnel, ainsi que le développement des états comportementaux du fœtus, constituent les plus importants facteurs d'altération des tracés de la FCF, dans des conditions normales et en réaction à l'hypoxémie. Il devient aussi évident que les fœtus manifestant un retard de croissance présentent des différences inhérentes quant aux tracés de la FCF par comparaison avec les fœtus dont la croissance est normale, peut-être en raison d'un retard de maturation du contrôle autonome du cœur fœtal en réaction à une hypoxémie chronique. Ainsi, pour recourir à la surveillance électronique de la FCF, le clinicien doit se familiariser avec la physiologie du fœtus, son évolution pendant le déroulement de la gestation et les divers moyens servant à représenter ces éléments dans les tracés de la FCF en cas de stress ou de souffrance. Grâce au perfectionnement de l'analyse informatisée de la FCF, qui élimine pratiquement les écarts d'interprétation entre les observateurs et chez le même observateur, en plus de la connaissance des facteurs ayant une incidence sur la FCF, il est maintenant possible d'effectuer rapidement un essai clinique randomisé, à grande échelle et bien conçu, pour vérifier si la surveillance de la FCF, à la fois avant la naissance et pendant l'intrapartum, pourra éventuellement devenir un outil utile pour exercer l'obstétrique.

J SOC OBSTET GYNAECOL CAN 1997;19:1385-91

## KEY WORDS

*Fetal heart rate, fetal monitoring, growth restriction.*

Received on April 15th, 1997. Revised and accepted on May 22nd, 1997.

## INTRODUCTION

Since its introduction into clinical practice in the mid-1970s, intrapartum continuous electronic fetal heart rate (FHR) monitoring has been the subject of controversy. Several recent randomized clinical trials comparing continuous FHR monitoring to intermittent FHR auscultation have failed to demonstrate any major benefit from the former method in relation to perinatal outcome.<sup>1</sup> However, there is a definite increase in operative deliveries including Caesarean sections in women who are continuously monitored. The goals when monitoring the fetus continuously during labour are to prevent intrapartum death and to detect the onset of metabolic acidosis requiring immediate intervention. However, to be clinically useful, a new technique such as continuous electronic FHR monitoring during labour needs to be validated in terms of reliability of interpretation prior to implementation. The purpose of this presentation is to review briefly the role of fetal heart rate monitoring in current practice and its limitations.

## FETAL BEHAVIOURAL STATES

It has been recognized that the human fetus near term experiences the organization of behavioural states much like the human neonate as described by Prechtel *et al.*<sup>2</sup> In the human fetus, these states are identified by the linkage of the three variables: body movements, eye

movements, and FHR pattern. These states have been referred to by Nijhuis *et al.* as 1F (quiet sleep), 2F (active sleep), 3F (quiet awake), and 4F (active awake).<sup>3</sup> The importance in recognizing the existence of these states in clinical practice is that their organization likely reflects a high degree of central nervous system function which, in turn, may influence the proper interpretation of FHR tracings. It is also possible to make the appropriately grown fetus change behavioural state by the application of vibro-acoustic stimulation (VAS) to the maternal abdomen.<sup>4,5</sup> Similar state changes occur with VAS in the fetus with intra-uterine growth restriction (IUGR), although the amplitude and duration of FHR response are shorter. In addition, the use of FHR response to VAS during labour has been suggested recently to differentiate the acidotic from the non-acidotic fetus.<sup>5</sup>

## INTERPRETATION OF FHR TRACINGS

The most widely used definition for a normal FHR tracing includes a baseline oscillation of > five bpm, a baseline FHR between 120 to 160 bpm, absence of periodic FHR decelerations, and the presence of FHR accelerations associated with fetal movements. It is expected that with a normal FHR pattern during labour, the fetus should be born with a good metabolic status. In contrast, an ominous FHR pattern is defined by a decrease in FHR variability, lack of FHR accelerations, loss of rest-activity

cycles, periodic FHR decelerations including late and severe variables, and terminal bradycardia. The ultimate fetal outcome in the presence of an ominous FHR pattern, if no intervention takes place, should be the development of progressive metabolic acidosis, intrapartum death, and possibly neurological sequelae in the survivors.<sup>6</sup>

There have been several attempts to validate and prove the reliability of visual interpretation of the different components of FHR tracings. Unfortunately, they reached the same conclusions. The intra-observer and interobserver agreements of visual interpretations of FHR tracings and their components have been uniformly low.<sup>7-10</sup> With the recent availability of computerized interpretation of FHR tracings, we have tried to compare visual interpretation of FHR tracings to a computer interpretation using the Oxford Sonicaid System 8000.<sup>10</sup> We asked five experts, well-trained in interpretation of FHR tracings, a total of seven questions on three readings of 100 FHR traces each. Judgement-related questions asked were:

1. Is the baseline FHR high, average or low?
2. Is the short-term FHR variability normal or decreased?
3. Should we continue recording? Yes or No?
4. Are you concerned about this tracing? Yes or No?

The accuracy-related questions were:


1. How many FHR accelerations of >15 bpm X >15 sec?
2. How many FHR decelerations of >10 bpm X >60 sec?
3. What is the baseline FHR in bpm?

The kappa coefficient was used to assess the reliability of the four judgement-related questions. The intra-observer agreement for the assessment of FHR baseline (range 0.53–0.82) was consistently higher than for FHR variability (range 0.03–0.58). One observer who was relatively consistent in assessing baseline FHR (kappa=0.76) and FHR variability (kappa=0.58) was inconsistent in deciding whether or not to continue FHR tracing (kappa=0.23) or to be concerned about an FHR trace (kappa=0.23). The interobserver agreement was poor for baseline FHR (kappa=0.44), FHR variability (kappa=0.18), continue or not? (kappa=0.39), and concerned or not? (kappa=0.26).

Accuracy of visual assessment for the detection of FHR accelerations, decelerations, and estimated baseline

compared with computerized FHR analysis was measured by comparing the first assessment of each observer with that of the computer.<sup>10</sup> When the computer detected < two FHR accelerations (a commonly used definition for an abnormal nonstress test), the observers did not agree with the computer one-third of the time. The five observers were highly accurate in assessing the absence of FHR decelerations. However, when they detected FHR decelerations on their first readings, they agreed with themselves only 58.3 percent of the time. When the computer detected FHR decelerations (35% of FHR tracings), observers saw zero deceleration > 90 percent of the time, indicating that the observers failed to recognize most FHR decelerations detected by the computer.

Figure 1, A through D, represents examples of FHR tracings during which agreement or disagreement between the computer and the observers was present in the detection of FHR decelerations. In one tracing (Figure 1A), all observers agreed with the computer. In contrast, Figure 1B illustrates a typical example of the 26 FHR tracings (74.3% of tracings with computer-detected FHR decelerations) during which small variables in decelerations occurred usually detected by the computer but not by the observers, causing the major source of disagreement between the computer and the observers. Figure 1C and 1D illustrate two examples during which the computer or observer may have difficulty in establishing the baseline FHR as a result of the absence of low heart rate variation caused by almost continuous fetal activity or a state of wakefulness. As a result, on one occasion the



computer recognized three FHR decelerations, although none of the observers detected them. During interpretation of another FHR tracing (Figure 1D), one observer who identified five decelerations was concerned about the tracing, but the computer recognized only one small FHR deceleration. It is, therefore, becoming evident that the poor level of accuracy in the different components used for interpretation of FHR tracings is responsible for the low interobserver agreement seen in such simple judgement-related questions as the decision to continue or to stop FHR recording. A second conclusion is that fetal behavioural state 4F (active wakefulness), characterized by large and long-lasting FHR accelerations frequently fused into sustained tachycardia, may be interpreted as a markedly abnormal tracing by an observer. We recently reported an erroneous computer interpretation of an FHR tracing as being "flat decelerative" with normal FHR variability due to the same phenomenon of fetal wakefulness.<sup>11</sup>

#### FETAL REST-ACTIVITY CYCLES

In the term human fetus, gross body movements (GBM) are closely associated with increases in the fetal heart rate (FHR) or accelerations.<sup>12-16</sup> In the premature fetus, the association between FHR accelerations and GBM is not as strong, with a large proportion of accelerations being less than 15 bpm in amplitude. Similarly, in the sheep fetus, 89 percent of FHR accelerations are associated with skeletal muscle activity. The majority of FHR accelerations (~60%) persist after neuromuscular blockade, suggesting that GBM and FHR accelerations occur together as a result of central neuronal output affecting both the cardio-accelerator fibres and the motoneurons simultaneously.

Episodic alternance between high FHR variability and low FHR variability typical of antepartum FHR tracings persists throughout labour. As decreased FHR variability is often quoted as an indication for fetal scalp sampling and is also typical of fetal quietness, it is important to determine how long is enough to wait when the fetus is in a quiet state before starting to be concerned.

Spencer and Johnson<sup>17</sup> using visual assessment of intrapartum FHR tracing, and Dawes *et al.*<sup>18</sup> using computerized FHR analysis reported the longest episode of low FHR variability in healthy fetuses to be 90 minutes. It seems reasonable, therefore, to use this value of 90 minutes as a minimum cut-off point for length of observation

of a flat FHR tracing during labour to differentiate between the fetus in a normal state of quietness and one that is possibly in distress and requiring active intervention, for example, fetal scalp sampling.

#### INTRAPARTUM FHR MONITORING AND PREDICTION OF FETAL ACIDOSIS

Based on animal and human studies, it is usually accepted that by using continuous electronic FHR monitoring, most of the fetuses developing metabolic acidosis during labour would be detected.<sup>19,20</sup> However, the Dublin randomized clinical trial demonstrated that only 15.6 percent of FHR abnormalities were associated with fetal acidosis with continuous FHR monitoring compared to 16.3 percent with intermittent auscultation.<sup>21</sup> These observations demonstrated the poor predictive value of FHR abnormalities for intrapartum fetal asphyxia. Spencer and Johnson,<sup>17</sup> using criteria of reduced FHR variability (baseline oscillation <5 bpm), reported a positive predictive value for the detection of intrapartum acidosis of only 32 percent. Using a more sophisticated computerized FHR analysis, Dawes *et al.*<sup>18</sup> were unable to demonstrate a significant correlation ( $r=.04$ ) between FHR variability during the last hour of FHR monitoring before delivery and umbilical arterial base deficit.

Subsequent observations by Pello *et al.*<sup>22</sup> failed to demonstrate a difference in baseline FHR, the number of FHR accelerations, the number of FHR decelerations with or without slow recovery, the area under the curve of FHR decelerations as recorded during the last hour of FHR tracing in fetuses born with either a normal pH, mild acidaemia, or moderate/severe acidosis. In only one out of 12 women delivered by Caesarean section for fetal distress, the umbilical artery base deficit was greater than 11 mmol/L, so the clinical diagnosis of fetal distress was not associated with severe acidaemia. Late FHR decelerations were of poor value (~30% positive predictive value) in predicting fetal acidaemia. There were no typical FHR patterns that could help to differentiate the acidotic from the non-acidotic fetus. However, gestational age and other physiological variables that could influence FHR reactivity were not taken into account.

#### ALTERATIONS IN BEHAVIOURAL STATES

In order to obviate the difficulties caused by the behavioural states and the alternance between episodes of rest and activity of the healthy fetus on FHR monitoring,

# OTC SHOWCASE

## CALCIUM SUPPLEMENTS

CALSAN® TABS (500 mg elemental calcium)  
Chewable tablets with a fresh, pleasing citrus flavour

CALSAN® CAPS (500 mg elemental calcium)  
Smooth, non-irritating soft gelatin capsules are easy to swallow

CALCIUM-SANDOZ®  
FORTE (500 mg elemental calcium)  
GRAMCAL® (1000 mg elemental calcium)  
SYRUP (110 mg elemental calcium/tsp. 5mL)

Novartis Consumer Health  
Canada Inc.  
Mississauga, Ontario  
L5N 2X7

CALSAN is a registered  
trademark of Novartis  
Consumer Health Canada Inc.  
CALCIUM-SANDOZ is a  
registered trademark of  
Novartis AG – Novartis  
Consumer Health Canada Inc.  
licensed user

PAAB

97692



## Lea® Contraceptive

- One size
- Safe and effective
- Latex free
- Available at your pharmacy



For more information, 1-800-305-4441:

Theramed Corporation  
385 Admiral Blvd., Unit 9  
Mississauga, Ontario L5T 2M8

## SMALL SAFE & EFFECTIVE

This latex barrier contraceptive device fits  
comfortably over the cervix.  
When used with spermicide it is highly effective.



CERVICAL CAP LTD.

430 Monterey Ave., Suite 1B  
Los Gatos, CA 95030

Tel. (408) 395-2100 Fax (408) 395-2103  
<http://www.cervcap.com>

## OTC SHOWCASE

JOURNAL SOGC'S NEW  
ADVERTISING FEATURE

For booking information and rates contact  
Norman Cook, Manager of Advertising Sales at  
Tel. (416) 322-5510 ext. 27 or Fax (416) 322-5263

several unsuccessful external stimuli to alter fetal behavioural states and FHR variability have been tried, including an external source of light, external manipulation of the fetus, and maternal ingestion of glucose. However, significant and reproducible alterations in fetal behaviour have been reported following vibro-acoustic stimulation (VAS).<sup>23</sup> Usually, an increase in FHR occurs following external VAS. This FHR response increases with advancing gestational age and with increasing intra-uterine sound pressure levels reached during stimulus. In contrast, during the progression of labour, after rupture of membranes, and in the presence of intra-uterine growth restriction, FHR response to VAS is reduced. In addition, the amplitude of FHR response to VAS is inversely related to the pre-stimulus baseline and is, therefore, of limited value in the presence of fetal tachycardia.

During labour, four different patterns of FHR response to VAS have been described,<sup>23</sup> including:

1. a prolonged period of acceleration (s) of >15 bpm for > three min;
2. one or more FHR accelerations of >15 seconds' duration;
3. a biphasic response with acceleration(s) followed by a prolonged FHR deceleration;
4. no FHR response or an FHR deceleration.

The overall positive predictive value of an abnormal FHR response for fetal distress during labour was <50 percent if the previous FHR pattern was not taken into account.

Intrapartum studies evaluating the relationship between FHR response to acoustic stimulation and fetal scalp pH used similar stimulus and the same criteria to define an adequate FHR response. Currently available data suggest the following.

1. The presence of an FHR acceleration following VAS during labour is associated with a fetal scalp pH >7.20 approximately 98 percent of the time. Occasionally, a normal FHR response can be seen in a fetus with significant metabolic acidosis.
2. The absence of an FHR acceleration following VAS during labour is a poor predictor of fetal metabolic acidosis, and should be followed by fetal scalp sampling to confirm the metabolic status of the fetus. If fetal scalp sampling cannot be done, the usual criteria of fetal distress using FHR patterns should be used to decide if immediate delivery is indicated or not.

## CONCLUSIONS

It is becoming increasingly evident that one of the major causes of misinterpretation of FHR tracings is the spontaneous change in fetal behavioural state that is a normal feature of a healthy human fetus. Growth-restricted fetuses also have an inherently low FHR variability when compared to normally-grown human fetuses which would make the interpretation more difficult, in addition to the changes seen with gestational age.<sup>4,24</sup> Visual interpretation of FHR tracings has been clearly shown to be unreliable. It is, therefore, possible that all the randomized clinical trials assessing the value of FHR monitoring in predicting the fetal metabolic status were doomed to fail due to the unreliability of visual interpretation. In order to use electronic FHR monitoring, it is becoming necessary for the clinician to start learning the physiology of the fetus, its changing evolution with advancing gestation, and the various ways that these are represented in FHR tracings under stress or distress. With the development of computerized FHR analysis that virtually eliminates inter-observer and intra-observer variation in interpretation, and the knowledge of the factors influencing FHR, it is now possible and timely to conduct a properly designed large-scale randomized clinical trial to demonstrate whether or not both antenatal and intrapartum FHR monitoring can ultimately become useful tools in obstetrical practice.

## REFERENCES

1. Thaker SB. The efficacy of intrapartum electronic fetal monitoring. *Am J Obstet Gynecol* 1987;156: 24-30.
2. Prechtl HFR, Akiyama Y, Zinkin P, et al. Polygraphic studies of the full-term newborn. I. Technical aspects and qualitative analysis, London, Heinemann. In: Ban MCO, MacKeith RC (Eds). *Studies in Infancy* (ed. 6). *Clin Dev Med* 1968;27:10-21.
3. Nijhuis JG, Prechtl HFR, Martin Jr. CB, et al. Are there behavioural states in the human fetus? *Early Hum Dev* 1982;6:177-95.
4. Gagnon R, Hunse C, Fellows F, et al. Fetal heart rate and activity patterns in growth-retarded fetuses: changes after vibratory acoustic stimulation. *Am J Obstet Gynecol* 1988;158:265-71.
5. Smith CV, Nguyen ITN, Phelan JP, et al. Intrapartum assessment of fetal well-being: a comparison of fetal acoustic stimulation with acid-base determinations. *Am J Obstet Gynecol* 1986;155:726-8.



6. Low JA, McGrath MJ, Marshall SJ, et al. The relationship between antepartum fetal heart rate, intrapartum fetal heart rate, and fetal acid-base status. *Am J Obstet Gynecol* 1986;154:769-76.
7. Borgatta L, Shrout PE, Divon MY. Reliability and reproducibility of nonstress test readings. *Am J Obstet Gynecol* 1988;159:554-8.
8. Lotgering FK, Wallenburg HSC, Schouten HJA. Interobserver and intraobserver variation in the assessment of antepartum cardiotocograms. *Am J Obstet Gynecol* 1982;144:701-5.
9. Hage ML. Interpretation of nonstress tests. *Am J Obstet Gynecol* 1985;153:490-5.
10. Gagnon R, Campbell K, Hunse C. A comparison between visual and computer analysis of antepartum fetal heart rate tracings. *Am J Obstet Gynecol* 1993;168:842-7.
11. Gagnon R, Bocking AD, Richardson BS, McLean P. A flat decelerative fetal heart rate tracing with normal fetal heart rate variability. *Am J Obstet Gynecol* 1994;171:1379-81.
12. Patrick J, Campbell K, Carmichael L, Natale R, Richardson B. Patterns of human fetal breathing during the last 10 weeks of pregnancy. *Obstet Gynecol* 1980;56:24-30.
13. Richardson B, Natale R, Patrick J. Human fetal breathing during the last 10 weeks of pregnancy. *Obstet Gynecol* 1979;133:247.
14. Patrick J, Campbell K, Carmichael L, Natale R, Richardson B. Patterns of gross fetal body movements over 24-hour observation intervals during the last 10 weeks of pregnancy. *Am J Obstet Gynecol* 1982;142:363-71.
15. Natale R, Nasello C, Turliuk R. The relationship between movements and accelerations in fetal heart rate at 24 to 32 weeks' gestation. *Am J Obstet Gynecol* 1984;148:591-5.
16. Bocking AD, Harding R, Wickham PJD. Relationships between accelerations and decelerations in heart rate and skeletal muscle activity in fetal sheep. *J Dev Physiol* 1985;7:47-54.
17. Spencer JAD, Johnson P. Fetal heart rate variability changes and fetal behavioural cycles during labour. *Br J Obstet Gynaecol* 1986;93:314-21.
18. Dawes GS, Rosevear SK, Pello LC, et al. Computerized analysis of episodic changes in fetal heart rate variation in early labor. *Am J Obstet Gynecol* 1991;165:618-24.
19. Murata Y, Martin CV, Ikenoue T, et al. Fetal heart rate accelerations and late decelerations during the course of intrauterine death in chronically catheterized rhesus monkeys. *Am J Obstet Gynecol* 1982;144:218-22.
20. Low JA, Cox MJ, Karchmar EJ, et al. The prediction of intrapartum fetal metabolic acidosis by fetal heart rate monitoring. *Am J Obstet Gynecol* 1981;139:299.
21. MacDonald D, Grant A, Sheridan-Pereira M, et al. The Dublin randomized controlled trial of intrapartum fetal heart rate monitoring. *Am J Obstet Gynecol* 1985;152:524-39.
22. Pello LC, Rosevear SR, Dawes GS, et al. Computerized fetal heart rate analysis in labor. *Obstet Gynecol* 1991;78:602-10.
23. Gagnon R. Stimulation of human fetuses with sound and vibration. *Semin Perinatol* 1989;13:393-402.
24. Murotsuki J, Bocking AD, Gagnon R. Fetal heart rate patterns in growth-restricted fetal sheep induced by chronic fetal placental embolization. *Am J Obstet Gynecol* 1997;176:282-90.